author-photo

Sriya W. Gunawardena

Janssen Pharmaceutica

3

Papers

37

Citations

Citation Trend

Filter By

Papers (3) Sort By

Journal Conference Others

Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma: LYRA study

2019 British Journal of Haematology
Show All
- Source
- Cite
- Save
Citations (28)
Lyra: A Phase 2 Study of Daratumumab (Dara) Plus Cyclophosphamide, Bortezomib, and Dexamethasone (Cybord) in Newly Diagnosed and Relapsed Patients (Pts) with Multiple Myeloma (MM)

2018 Blood
Show All
- Source
- Cite
- Save
Citations (9)
1036TiPPhase 2, multicenter, single-arm, open label study evaluating the combination of daratumumab + cyclophosphamide, bortezomib and dexamethasone (Dara-CyBorD) in previously untreated and relapsed patients (pts) with multiple myeloma (MM)

2017 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)